QHP Capital completes $1.1bn continuation fund for Azurity Pharmaceuticals
Thursday, March 19, 2026 · first reported by PE Hub and 1 other
QHP Capital has achieved a $1.1bn final close for a single-asset continuation vehicle backing portfolio company Azurity Pharmaceuticals, with support from secondaries investors HarbourVest and Pantheon. The continuation fund enables QHP to extend its investment horizon in the pharmaceutical portfolio business.
- Firm
- QHP Capital
- Also named
- HarbourVest Partners, Pantheon Ventures
- Fund
- Azurity Pharmaceuticals continuation fund
- Size
- $1.1B
- Stage
- Final close
- Asset class
- Private equity
- Geography
- North America
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
Coverage
2 sourcesMore in Private equity
From the same day- Co-investments drive Truelink’s sophomore fund to $2bn close in three monthsBuyouts +1
- Ares leads €300m Europastry continuation fundPrivate Equity Wire +2
- Partners Group seeks to raise at least $1 billion in India-focused buyout fundReuters
- Adenia Partners speeds to one-and-done $180m hard cap for new smaller-cap Africa fundAltAssets +4
- Blackstone leads $1.3bn private financing for Paratek-Radius Pharma mergerPrivate Equity Wire +1
- Adenia Partners hits final close of SME-focussed PE fundVCCircle